Spots Global Cancer Trial Database for A Study of a New Investigational Medicinal Product to Treat Patients With Advanced or Metastatic Solid Tumors

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: A Study of a New Investigational Medicinal Product to Treat Patients With Advanced or Metastatic Solid Tumors

Official Title: Phase I/II Open Label Dose Escalation and Dose Expansion Study of Intravenous Infusion of W0101, an Antibody-drug Conjugate, in Patients With Advanced or Metastatic Solid Tumors. International, Multicenter, Open Label Study

Study ID: NCT03316638

Conditions

Advanced or Metastatic Solid Tumors

Interventions

W0101 - Cohort A1

W0101 - Cohort A2

W0101 - Expansion Phase

Study Description

Brief Summary: W0101 combines a cytotoxic compound to a monoclonal antibody targeting a receptor commonly overexpressed in many cancers. The development of antibody-drug conjugates takes advantage of the specificity of the mAb while augmenting its ability to produce a cytotoxic effect. The expected benefits of antibody-drug conjugation are enhancement of cytotoxicity in target cells and limiting toxicities of cytotoxic drugs in normal tissues.

Detailed Description: This is a First In Human study, multicenter, open label study divided into 2 parts: an initial dose escalation phase (I) followed by expansion cohort(s) phase (II).